RAPT Therapeutics Company Insiders
RAPT Stock | USD 1.13 0.04 3.42% |
Slightly above 80 percent of RAPT Therapeutics' insiders are selling. The analysis of the overall insider sentiment regarding RAPT Therapeutics suggests that a fairly large number of insiders are terrified. RAPT Therapeutics employs about 70 people. The company is managed by 12 executives with a total tenure of roughly 164 years, averaging almost 13.0 years of service per executive, having 5.83 employees per reported executive.
Insider Sentiment 20
Mostly Selling
Selling | Buying |
Latest Trades
2024-01-05 | Dirk G Brockstedt | Disposed 898 @ 22.78 | View | ||
2023-12-21 | William Ho | Disposed 2500 @ 21.68 | View | ||
2023-11-28 | William Ho | Disposed 1500 @ 13.72 | View | ||
2023-10-03 | William Ho | Disposed 2500 @ 15.77 | View | ||
2023-08-18 | William Ho | Disposed 2500 @ 18.92 | View | ||
2023-04-19 | William Ho | Disposed 5000 @ 18.88 | View | ||
2023-03-14 | Wendye Robbins | Acquired 2500 @ 18.99 | View | ||
2023-03-07 | William Ho | Disposed 5000 @ 29.62 | View | ||
2023-01-24 | William Ho | Disposed 5000 @ 30 | View | ||
2023-01-19 | William Ho | Disposed 5000 @ 25.56 | View | ||
2023-01-05 | Dirk G Brockstedt | Disposed 742 @ 21.97 | View | ||
2022-12-29 | William Ho | Disposed 5000 @ 18.03 | View | ||
2022-11-28 | William Ho | Disposed 5000 @ 17.87 | View | ||
2022-11-02 | William Ho | Disposed 5000 @ 22.32 | View | ||
2022-10-13 | William Ho | Disposed 2000 @ 21.52 | View | ||
2022-08-30 | William Ho | Disposed 2500 @ 28.13 | View | ||
2022-07-11 | William Ho | Disposed 2000 @ 19.95 | View | ||
2022-05-25 | Group Ii Lp Column | Acquired 1900 @ 12.45 | View | ||
2022-05-23 | Group Ii Lp Column | Acquired 10236 @ 12.5 | View | ||
2022-05-10 | Group Ii Lp Column | Acquired 1250000 @ 10.67 | View |
Monitoring RAPT Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
RAPT |
RAPT Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4658) % which means that it has lost $0.4658 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8013) %, meaning that it created substantial loss on money invested by shareholders. RAPT Therapeutics' management efficiency ratios could be used to measure how well RAPT Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.64 in 2025. Return On Capital Employed is likely to drop to -0.79 in 2025. Total Current Liabilities is likely to gain to about 26.4 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 151.1 M in 2025.Common Stock Shares Outstanding is likely to drop to about 27.7 M in 2025. Net Loss is likely to drop to about (79.2 M) in 2025
RAPT Therapeutics Workforce Comparison
RAPT Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,119. RAPT Therapeutics holds roughly 70.0 in number of employees claiming about 3% of equities under Health Care industry.
RAPT Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific RAPT Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on RAPT Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, RAPT Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
RAPT Therapeutics Notable Stakeholders
A RAPT Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as RAPT Therapeutics often face trade-offs trying to please all of them. RAPT Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting RAPT Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Brian MD | President CEO | Profile | |
Gwen Carscadden | Chief Officer | Profile | |
Rodney Young | Principal CFO | Profile | |
David Wustrow | Senior Development | Profile | |
William Ho | Chief Officer | Profile | |
Jennifer Nicholson | Senior Assurance | Profile | |
Michael Listgarten | General Counsel | Profile | |
William MD | Chief Officer | Profile | |
Steve Young | Vice Technology | Profile | |
Paul Kassner | Senior Biology | Profile | |
Nipun MBA | Senior Operations | Profile | |
Dirk Brockstedt | Chief Officer | Profile |
About RAPT Therapeutics Management Performance
The success or failure of an entity such as RAPT Therapeutics often depends on how effective the management is. RAPT Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of RAPT management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the RAPT management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.61) | (0.64) | |
Return On Capital Employed | (0.75) | (0.79) | |
Return On Assets | (0.61) | (0.64) | |
Return On Equity | (0.91) | (0.87) |
Please note, the imprecision that can be found in RAPT Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of RAPT Therapeutics. Check RAPT Therapeutics' Beneish M Score to see the likelihood of RAPT Therapeutics' management manipulating its earnings.
RAPT Therapeutics Workforce Analysis
Traditionally, organizations such as RAPT Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare RAPT Therapeutics within its industry.RAPT Therapeutics Manpower Efficiency
Return on RAPT Therapeutics Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.7M | |
Net Loss Per Executive | 9.7M | |
Working Capital Per Employee | 2M | |
Working Capital Per Executive | 11.7M |
Additional Tools for RAPT Stock Analysis
When running RAPT Therapeutics' price analysis, check to measure RAPT Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RAPT Therapeutics is operating at the current time. Most of RAPT Therapeutics' value examination focuses on studying past and present price action to predict the probability of RAPT Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RAPT Therapeutics' price. Additionally, you may evaluate how the addition of RAPT Therapeutics to your portfolios can decrease your overall portfolio volatility.